Savara Total Current Liabilities 2010-2024 | SVRA

Savara total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.

Savara Total Current Liabilities 2010-2024 | SVRA

Savara total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$78.5B
Takeda Pharmaceutical (TAK)$43.1B
Merck (MKKGY)$20.8B
Astellas Pharma (ALPMY)$19.8B
Sandoz Group AG (SDZNY)$19.4B
United Therapeutics (UTHR)$17.9B
Summit Therapeutics (SMMT)$15.3B
Neurocrine Biosciences (NBIX)$12.9B
Shionogi (SGIOY)$12.2B
Catalent (CTLT)$10.8B
Jazz Pharmaceuticals (JAZZ)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.4B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$6.1B
Ionis Pharmaceuticals (IONS)$6B
Crinetics Pharmaceuticals (CRNX)$4.7B
PTC Therapeutics (PTCT)$3.4B
Dyne Therapeutics (DYN)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2.1B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.8B
Xencor (XNCR)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
ARS Pharmaceuticals (SPRY)$1.6B